SJ10542 is a selective PROTAC degrader targeting Janus kinases JAK2 and JAK3. Public product information describes it as a potent JAK2/3 degrader used in research models involving JAK-STAT signaling, but accessible summaries do not fully specify the atom-level kinase-binding site or the recruited E3 ligase identity in the brief description. In PROTAC design, the kinase-recognition element is expected to engage JAK-family kinase domains, while the linker and E3-recruiting module create a ternary complex that supports ubiquitination. Mechanistically, SJ10542 reduces JAK2 and JAK3 protein levels through targeted degradation, enabling investigation of pathway suppression by protein depletion rather than transient kinase inhibition. It is useful for studying JAK-STAT pathway dependence, kinase-family selectivity, hematologic malignancy and immune-signaling models, degrader-induced signaling collapse, and comparative analysis of JAK catalytic inhibitors versus JAK protein degraders.
Structure of 2789678-92-6
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Target: SJ10542 selectively targets Janus kinases JAK2 and JAK3 for degradation.
Binding site: Its kinase-binding ligand engages the ATP-binding catalytic clefts of JAK2 and JAK3.
Mechanism of action: SJ10542 is a CRBN-recruiting JAK2/3 PROTAC designed to induce selective degradation of JAK family kinases through the ubiquitin-proteasome system. The molecule contains a JAK2/3-recognition ligand connected to a phenyl glutarimide cereblon recruiter, promoting ternary-complex formation with CRL4CRBN and subsequent ubiquitination of bound kinases. This degradation mechanism enables sustained attenuation of JAK-STAT signaling and helps distinguish target depletion from reversible kinase inhibition. SJ10542 is useful for studying JAK2 fusion biology, JAK3 contribution, degradation selectivity, and signaling dependencies in hematologic or immune-cell models.
Applications• PROTAC-Mediated Oncoprotein Degradation: SJ10542 is utilized in cancer research to selectively degrade oncogenic proteins, offering a novel approach to target proteins previously considered "undruggable." This facilitates the study of cancer cell proliferation and survival, advancing the understanding of tumor biology and potential therapeutic interventions.
• Targeted Kinase Degradation: Researchers employ SJ10542 to investigate the degradation of specific kinases involved in signaling pathways. This application aids in dissecting complex cellular processes and determining the role of kinases in disease progression, providing insights into potential targets for drug development.
• Neurodegenerative Disease Research with PROTACs: SJ10542 is applied to study the degradation of proteins implicated in neurodegenerative diseases. By facilitating the removal of pathogenic proteins, this approach helps elucidate disease mechanisms and explore new avenues for therapeutic strategies in disorders such as Alzheimer's and Parkinson's.
• Protein-Protein Interaction Modulation: SJ10542 serves as a tool to study the effects of degrading protein complexes involved in cellular functions. This application enhances the understanding of protein interaction networks and their implications in various biological processes, supporting the development of innovative research methodologies.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.